简介：TheaimofthepresentstudywastodeterminetheefficacyofimmunotherapywithdendriticcellstoelicitEBV-specificCTL-immunityinadvancedcasesofEBV-positivepatientswithnasopharyngealcarcinoma(NPC)andtodeterminethesafetyandtoxicityofthispreparation.NinecasesofhistologicallyconfirmedpatientswithNPCundergoingtreatmentwithradiologicaltherapywereenrolledinthisstudy.Dendriticcells,generatedinvitrofrombloodmonocytesofpatientswereculturedandmaturedwithcytokinesandtheninfectedwithrecombinantadenovirusvaccinecontainingEBV-latentmembraneprotein-2(Ad-LMP2).On9days'cultivationofcells,thematuredDCswereharvested,irradiatedwithCoandtheninjectedintradermallytopatientswithNPC.Theinjectionswereperformed3timestotally.Afterimmunization,theCTLresponseswereassayedbymeansofcytotoxicityandepitope-specificIFN-γproduction.Theresultsofthistrialshowedthatallpatientscouldtoleratethiskindoftreatmentwithoutanysideeffect,duringwhichmarkedincreaseofLMP2-specificCTL-responsescouldbedemonstratedin5patientsofthisgroup.AndthelevelofIgA/VCAantibodydecreasedin8of9patients,thusaccountingforabetterprognosisforthesepatients.Allpatientswillbefollowedupforanotheroneyear.Atleast,thepresentworkshowsthatintradermalvaccinationwithautologousDCsinfectedwithrecombinantAd-LMP2adenovirusisasafeprocedureinNPCpatients,inwhichthisprocedurecanenhancetheLMP2-specificCTLresponsesinpatients.Thesedataareencouragingtodevelopmoreeffectivevaccinestrategiesforthetreatmentofnasopharyngealcarcinoma.

简介：

简介：Wehaveconfirmedefficientanti-tumoractivitiesoftheperipherallymphocytestransducedwithap185HER2-specificchimericT-cellreceptorgenebothinmurineandinhumaninourpreviousstudies.TofurthertestthefeasibilityofchimericT-cellreceptorinabonemarrowtransplantationmodel,wefirst,madetwomurinetumorcelllines:MT901andMCA-205,toexpresshumanp185HER2byretroviralgenetransduction.MurinebonemarrowcellswereretrovirallytransducedtoexpressthechimericT-cellreceptorandgene-modifiedbonemarrowcellsweretransplantedintolethallyirradiatedmouse.Sixmonthsposttransplantation,p185HER2-positivetumorcells:MT-901/HER2orMCA-205/HER2wassubcutaneouslyorintravenouslyinjectedtomakemousemodelssimulatingprimarybreastcancerorpulmonarymetastasis.Theinvivoanti-tumoreffectsweremonitoredbythesizeofthesubcutaneoustumororcountingthetumornodulesinthelungsafterIndiainkstaining.ThesizeofthesubcutaneoustumorwassignificantlyinhibitedandthenumberofpulmonarynodulesweresignificantlydecreasedinmouserecipientstransplantedwithchimericT-cellreceptormodifiedbonemarrowcellscomparedwiththecontrolgroup.Ourresultssuggesttheefficientinvivoanti-tumoractivitiesofchimericT-cellreceptorgenemodifiedbonemarrowcells.